我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
3
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2019
招募中
2
66.7%
撤回
1
33.3%
暂无批准数据
- Astellas Pharma and AviadoBio have entered into an agreement potentially worth $2.2 billion to advance AVB-101, a gene therapy for frontotemporal dementia with progranulin mutations (FTD-GRN). - AVB-101 is currently in Phase I/II development and aims to restore progranulin levels in the brain via a one-time, targeted delivery. - The collaboration includes an upfront payment and equity investment from Astellas, with potential milestone payments and royalties upon exercising the license option. - Frontotemporal dementia is a devastating early-onset dementia with no current cure, highlighting the urgent need for new treatments like AVB-101.
